l-371257 and Autism-Spectrum-Disorder

Currently, there are no medications that effectively treat the core symptoms of Autism Spectrum Disorder (ASD). We recently found that the bacterial species Lactobacillus (L.) reuteri reverses social deficits in maternal high-fat-diet offspring. However, whether the effect of L. reuteri on social behavior is generalizable to other ASD models and its mechanism(s) of action remains unknown. Here, we found that treatment with L. reuteri selectively rescues social deficits in genetic, environmental, and idiopathic ASD models. Interestingly, the effects of L. reuteri on social behavior are not mediated by restoring the composition of the host's gut microbiome, which is altered in all of these ASD models. Instead, L. reuteri acts in a vagus nerve-dependent manner and rescues social interaction-induced synaptic plasticity in the ventral tegmental area of ASD mice, but not in oxytocin receptor-deficient mice. Collectively, treatment with L. reuteri emerges as promising non-invasive microbial-based avenue to combat ASD-related social dysfunction.

Topics: Action Potentials; Animals; Autism Spectrum Disorder; Benzoxazines; Capillary Permeability; Central Nervous System Stimulants; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Exploratory Behavior; Gastrointestinal Microbiome; Humans; Interpersonal Relations; Limosilactobacillus reuteri; Male; Mice; Mice, Transgenic; Microfilament Proteins; Nerve Tissue Proteins; Picrotoxin; Piperidines; Receptors, Oxytocin; Smell; Social Behavior Disorders; Valproic Acid